Difference between revisions of "Main Page"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 14: Line 14:
 
</div>
 
</div>
  
−
{| border="1"; style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
+
{| class="wikitable" style="text-align:center; margin-left: auto; margin-right: auto; font-size:125%; font-weight: bold; width: 100%;"
 
|-
 
|-
−
|colspan="2" style="background-color:#F0F0F0"|'''[[Tutorial#Regimens|Regimens]]:<big> {{#ask: [[Regimen::+]] |?Regimen |limit=10000|format=sum}}</big>'''
+
!colspan="6" style="font-size:150%"|[[Tutorial#Regimens|Regimens]]: {{#ask: [[Regimen::+]] |?Regimen |limit=10000|format=sum}}
−
|colspan="2" style="background-color:#F0F0F0"|'''[[Tutorial#Variants|Regimen variants]]:<big> {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}</big>'''
+
!colspan="6" style="font-size:150%"|[[Tutorial#Variants|Regimen variants]]: {{#ask: [[Variant::+]] |?Variant |limit=10000|format=sum}}
 
|-
 
|-
−
|style="width: 25%; border-left:solid 20px #3182bd; background-color:#deebf7"|[[#solidtumors|Solid Tumors]]  
+
|colspan="3" style="width: 25%; font-size:125%; background-color:#deebf7"|[[#solidtumors|Solid Tumors]]  
−
|style="width: 25%; border-left:solid 20px #de2d26; background-color:#fee0d2"|[[#malignantheme|Malignant Hematology]]
+
|colspan="3" style="width: 25%; font-size:125%; background-color:#fee0d2"|[[#malignantheme|Malignant Hematology]]
−
|style="width: 25%; border-left:solid 20px #756bb1; background-color:#efedf5"|[[#transplant|Transplant]]
+
|colspan="3" style="width: 25%; font-size:125%; background-color:#efedf5"|[[#transplant|Transplant]]
−
|style="width: 25%; border-left:solid 20px #31a354; background-color:#e5f5e0"|[[#classicalheme|Classical Hematology]]
+
|colspan="3" style="width: 25%; font-size:125%; background-color:#e5f5e0"|[[#classicalheme|Classical Hematology]]
 
|-
 
|-
−
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]'''
+
|colspan="2" style="width: 17.5%"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_mobile Mobile Version]'''
−
|colspan="2" style="background-color:#F0F0F0"|<big>[[Editorial Board]]</big>
+
|colspan="8" |[[Editorial Board]]
−
|style="background-color:#F0F0F0"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_desktop Desktop Version]'''
+
|colspan="2" style="width: 17.5%"|'''[https://hemonc.org/w/index.php?title=Main_Page&mobileaction=toggle_view_desktop Desktop Version]'''
 
|-
 
|-
−
|[[:Category:Disease index|Disease index]]
+
|colspan="3"|[[:Category:Disease index|Disease index]]
−
|[[:Category:Drug index|Drug index]]
+
|colspan="3"|[[:Category:Drug index|Drug index]]
−
|[[:Category:Regimen index|Regimen index]]
+
|colspan="3"|[[:Category:Regimen index|Regimen index]]
−
|[[:Category:General reference pages|General reference]]
+
|colspan="3"|[[:Category:General reference pages|General reference]]
 
|-
 
|-
 
|}  
 
|}  
Line 42: Line 42:
 
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#3182bd"| '''Solid Tumors'''
 
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#3182bd"| '''Solid Tumors'''
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Breast Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Breast Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Breast cancer]]
 
|style="background-color:#deebf7"|[[Breast cancer]]
Line 49: Line 49:
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Dermatologic Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Dermatologic Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Melanoma]]  
 
|style="background-color:#deebf7"|[[Melanoma]]  
Line 56: Line 56:
 
|style="background-color:#deebf7"|[[Merkel cell carcinoma]]  
 
|style="background-color:#deebf7"|[[Merkel cell carcinoma]]  
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Endocrine Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Endocrine Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Adrenocortical carcinoma]]
 
|style="background-color:#deebf7"|[[Adrenocortical carcinoma]]
Line 68: Line 68:
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Gastrointestinal Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Gastrointestinal Oncology'''
 
|-
 
|-
 
|style="width: 25%; background-color:#deebf7"|[[Anal cancer]]
 
|style="width: 25%; background-color:#deebf7"|[[Anal cancer]]
Line 85: Line 85:
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Genitourinary Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Genitourinary Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Bladder cancer]]
 
|style="background-color:#deebf7"|[[Bladder cancer]]
Line 97: Line 97:
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Gynecologic Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Gynecologic Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Cervical cancer]]
 
|style="background-color:#deebf7"|[[Cervical cancer]]
Line 104: Line 104:
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Head & Neck Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Head & Neck Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Head and neck cancer]]
 
|style="background-color:#deebf7"|[[Head and neck cancer]]
Line 111: Line 111:
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Neuro-Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Neuro-Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Anaplastic glioma]]
 
|style="background-color:#deebf7"|[[Anaplastic glioma]]
Line 118: Line 118:
 
|style="background-color:#deebf7"|[[Meningioma]]
 
|style="background-color:#deebf7"|[[Meningioma]]
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Pediatric Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Pediatric Oncology'''
 
|-
 
|-
 
|colspan="4" style="background-color:#deebf7"|[[Neuroblastoma]]
 
|colspan="4" style="background-color:#deebf7"|[[Neuroblastoma]]
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Sarcoma'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Sarcoma'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Bone sarcoma]]  
 
|style="background-color:#deebf7"|[[Bone sarcoma]]  
Line 134: Line 134:
 
|style="background-color:#deebf7"|
 
|style="background-color:#deebf7"|
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Thoracic Oncology'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Thoracic Oncology'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[Esophageal cancer]]
 
|style="background-color:#deebf7"|[[Esophageal cancer]]
Line 146: Line 146:
 
|style="background-color:#deebf7"|[[Thymoma]]
 
|style="background-color:#deebf7"|[[Thymoma]]
 
|-
 
|-
−
|colspan="4" style="background-color:#9ecae1"|'''Site-agnostic'''
+
|colspan="4" style="font-size:125%; background-color:#9ecae1"|'''Site-agnostic'''
 
|-
 
|-
 
|style="background-color:#deebf7"|[[MSI-H or dMMR]]
 
|style="background-color:#deebf7"|[[MSI-H or dMMR]]
Line 162: Line 162:
 
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#de2d26"| '''Malignant Hematology'''
 
!colspan="4" align="center" style="color:white; font-size:150%; background-color:#de2d26"| '''Malignant Hematology'''
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Acute leukemias'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Acute leukemias'''
 
|-
 
|-
 
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
 
|style="width: 25%; background-color:#fee0d2"|[[Acute myeloid leukemia | Acute myeloid leukemia (AML)]]
Line 174: Line 174:
 
|style="background-color:#fee0d2"|[[CNS leukemia]]
 
|style="background-color:#fee0d2"|[[CNS leukemia]]
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Myeloproliferative neoplasms and myelodysplastic syndromes'''
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
 
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia | Chronic myelogenous leukemia (CML)]]
Line 186: Line 186:
 
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
 
|style="background-color:#fee0d2"|[[Systemic mastocytosis]]
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Aggressive lymphomas'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Aggressive lymphomas'''
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
 
|style="background-color:#fee0d2"|[[Burkitt lymphoma|Burkitt lymphoma (BL) or Burkitt-like lymphoma]]
Line 203: Line 203:
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Indolent lymphomas'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Indolent lymphomas'''
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia (CLL/SLL) | Chronic lymphocytic leukemia (CLL/SLL)]]
 
|style="background-color:#fee0d2"|[[Chronic lymphocytic leukemia (CLL/SLL) | Chronic lymphocytic leukemia (CLL/SLL)]]
Line 215: Line 215:
 
|style="background-color:#fee0d2"|
 
|style="background-color:#fee0d2"|
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Plasma cell dyscrasias'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Plasma cell dyscrasias'''
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
 
|style="background-color:#fee0d2"|[[Light-chain (AL) amyloidosis]]
Line 222: Line 222:
 
|style="background-color:#fee0d2"|[[POEMS]]
 
|style="background-color:#fee0d2"|[[POEMS]]
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''T-cell and NK-cell neoplasms'''
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
 
|style="background-color:#fee0d2"|[[Adult T-cell leukemia-lymphoma|Adult T-cell leukemia-lymphoma (ATLL)]]
Line 234: Line 234:
 
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]]
 
|style="background-color:#fee0d2"|[[T-cell acute lymphoblastic leukemia | T-cell acute lymphoblastic lymphoma (T-LBL)]]
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Lymphoproliferative disorders'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Lymphoproliferative disorders'''
 
|-
 
|-
 
|colspan="2" style="background-color:#fee0d2"|[[Castleman disease]]
 
|colspan="2" style="background-color:#fee0d2"|[[Castleman disease]]
 
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
|colspan="2" style="background-color:#fee0d2"|[[Post-transplant lymphoproliferative disorder|Post-transplant lymphoproliferative disorder (PTLD)]]
 
|-
 
|-
−
|colspan="4" style="background-color:#fc9272"|'''Histiocyte disorders'''
+
|colspan="4" style="font-size:125%; background-color:#fc9272"|'''Histiocyte disorders'''
 
|-
 
|-
 
|style="background-color:#fee0d2"|[[Erdheim-Chester disease]]
 
|style="background-color:#fee0d2"|[[Erdheim-Chester disease]]
Line 269: Line 269:
 
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
 
|colspan="4" align="center" style="color:white; font-size:150%; background-color:#31a354"|'''Classical Hematology'''
 
|-
 
|-
−
|colspan="4" style="background-color:#a1d99b"|'''Hemostasis and thrombosis'''
+
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemostasis and thrombosis'''
 
|-
 
|-
 
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Acquired coagulopathy]]
Line 276: Line 276:
 
|style="width: 25%; background-color:#e5f5e0"|[[Venous thromboembolism (VTE)]]
 
|style="width: 25%; background-color:#e5f5e0"|[[Venous thromboembolism (VTE)]]
 
|-
 
|-
−
|colspan="4" style="background-color:#a1d99b"|'''Cytopenias'''
+
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Cytopenias'''
 
|-
 
|-
 
|style="background-color:#e5f5e0"|[[Aplastic anemia]]
 
|style="background-color:#e5f5e0"|[[Aplastic anemia]]
Line 283: Line 283:
 
|style="background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia (HIT)]]
 
|style="background-color:#e5f5e0"|[[Heparin-induced thrombocytopenia (HIT)]]
 
|-
 
|-
−
|colspan="4" style="background-color:#a1d99b"|'''Hemolytic disorders'''
+
|colspan="4" style="font-size:125%; background-color:#a1d99b"|'''Hemolytic disorders'''
 
|-
 
|-
 
|style="background-color:#e5f5e0"|[[Atypical hemolytic-uremic syndrome (aHUS)]]
 
|style="background-color:#e5f5e0"|[[Atypical hemolytic-uremic syndrome (aHUS)]]
Line 300: Line 300:
  
 
==Additional Information==
 
==Additional Information==
−
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100s of hematology/oncology drugs, and 1000s of antineoplastic regimens. Content is added by hematology & oncology providers, and undergoes [[how to contribute|continuous peer review]].
+
Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100's of hematology/oncology drugs, and 1000's of treatment regimens. Content is added by hematology & oncology professionals, and undergoes [[how to contribute|continuous peer review]].
  
 
<br><inputbox>
 
<br><inputbox>
Line 307: Line 307:
 
placeholder=Type the name of the page you want to create  
 
placeholder=Type the name of the page you want to create  
 
break=no  
 
break=no  
−
</inputbox>
+
</inputbox>
−
Any information that one feels would be helpful to other oncology providers is welcome. Visit [[how to contribute]] for more details. Priorities of this project include:
+
Any information that one feels would be helpful to other oncology providers is welcome. Visit [[how to contribute]] for more details.
  
−
#Creating a database of [[Drug index | chemotherapy agents and other medications]].
+
Priorities of this project include:
−
#Creating a database of chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
+
*Creating a database of all [[Drug index | FDA-approved chemotherapy agents and supportive medications used in the field of hematology/oncology]].
−
#[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
+
*Creating a database of all standard-of-care chemotherapy regimens and references to primary literature (PubMed and direct links to the abstracts/full articles).
−
#Aggregating [[External links|useful links]] to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.
+
*[[:Category:Example chemotherapy order sets|Sample order sets]] and examples of supportive medications used with treatment regimens
 +
*Aggregating [[External links|useful links]] to existing resources by disease, such as information about prognosis, clinical calculators, staging, and patient resources.
  
 
Additional possibilities for this project may include:
 
Additional possibilities for this project may include:
−
#Creating summaries of pivotal clinical trials
+
*Creating summaries of pivotal clinical trials
−
#Establishing homepages for ongoing clinical trials that contain information and sites of participation
+
*Prioritizing regimens by their efficacy and/or toxicity
−
#Checklists for common clinical scenarios/diseases
+
*Capturing historical regimens that were standard-of-care prior to 2005
−
#Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
+
*Checklists for common clinical scenarios/diseases
 +
*Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
  
−
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [http://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.
+
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as [http://en.wikipedia.org/wiki/Main_Page Wikipedia], will significantly help ease-of-use and navigation.

Revision as of 22:53, 10 January 2018

 Hello!
 We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.
 Please help us by filling it out!
 Link: http://j.mp/2BlBaoQ



HemOnc.org - A Free Hematology/Oncology Reference

Regimens: 4,428 Regimen variants: 6,546
Solid Tumors Malignant Hematology Transplant Classical Hematology
Mobile Version Editorial Board Desktop Version
Disease index Drug index Regimen index General reference
If this is your first time visiting, please go to the tutorial page or just start exploring!

Links to all main disease pages

Solid Tumors
Breast Oncology
Breast cancer Breast cancer, HER2-positive Breast cancer, triple negative (TNBC)
Dermatologic Oncology
Melanoma Melanoma, BRAF-mutated Skin, basal & squamous cancer Merkel cell carcinoma
Endocrine Oncology
Adrenocortical carcinoma Neuroendocrine tumors Pancreatic NET Pheochromocytoma
Thyroid cancer
Gastrointestinal Oncology
Anal cancer Cholangiocarcinoma Colon cancer Esophageal cancer
Gastric cancer Gastrointestinal stromal tumor (GIST) Hepatocellular carcinoma Periampullary adenocarcinoma
Pancreatic cancer Pancreatic NET Rectal cancer
Genitourinary Oncology
Bladder cancer Penile cancer Prostate cancer Renal cancer (RCC)
Testicular cancer
Gynecologic Oncology
Cervical cancer Ovarian cancer Uterine cancer
Head & Neck Oncology
Head and neck cancer Nasopharyngeal carcinoma Thyroid cancer
Neuro-Oncology
Anaplastic glioma Glioblastoma Low-grade glioma Meningioma
Pediatric Oncology
Neuroblastoma
Sarcoma
Bone sarcoma Ewing's sarcoma Gastrointestinal stromal tumor (GIST) Osteosarcoma
Soft tissue sarcoma (STS) Vascular sarcoma
Thoracic Oncology
Esophageal cancer Lung cancer, non-small cell (NSCLC) NSCLC, ALK-positive NSCLC, BRAF-mutated
NSCLC, EGFR-mutated Lung cancer, small cell (SCLC) Mesothelioma Thymoma
Site-agnostic
MSI-H or dMMR Adenocarcinoma of unknown primary NET of unknown primary SCC of unknown primary

back to top
Malignant Hematology
Acute leukemias
Acute myeloid leukemia (AML) AML, FLT3-positive AML, IDH-mutated Acute promyelocytic leukemia (APL)
B-cell acute lymphoblastic leukemia (B-ALL) B-ALL, Ph+ T-cell acute lymphoblastic leukemia (T-ALL) CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
Chronic myelogenous leukemia (CML) Chronic myelomonocytic leukemia (CMML) Essential thrombocythemia (ET) Hypereosinophilic syndrome (HES)
Myelodysplastic syndrome Primary & secondary myelofibrosis Polycythemia vera (PV) Systemic mastocytosis
Aggressive lymphomas
Burkitt lymphoma (BL) or Burkitt-like lymphoma CNS lymphoma Diffuse large B-cell lymphoma (DLBCL) HIV-associated lymphoma
Hodgkin lymphoma (HL) Mantle cell lymphoma (MCL) Mediastinal gray-zone lymphoma (MGZL) Primary mediastinal B-cell lymphoma (PMBL)
Transformed lymphoma (TL)
Indolent lymphomas
Chronic lymphocytic leukemia (CLL/SLL) Follicular lymphoma (FL) Hairy cell leukemia (HCL) Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
Marginal zone lymphoma (MZL) Waldenström macroglobulinemia (WM/LPL)
Plasma cell dyscrasias
Light-chain (AL) amyloidosis Multiple myeloma (MM) Plasma cell leukemia POEMS
T-cell and NK-cell neoplasms
Adult T-cell leukemia-lymphoma (ATLL) Anaplastic large cell lymphoma (ALCL) Cutaneous T-cell lymphoma (CTCL) Extranodal NK/T-cell lymphoma, nasal type
Large granular lymphocytic (LGL) leukemia NK/T-cell lymphoma Peripheral T-cell Lymphoma (PTCL) T-cell acute lymphoblastic lymphoma (T-LBL)
Lymphoproliferative disorders
Castleman disease Post-transplant lymphoproliferative disorder (PTLD)
Histiocyte disorders
Erdheim-Chester disease Hemophagocytic lymphohistiocytosis (HLH) Langerhans cell histiocytosis

back to top
Transplant
Stem cell mobilization Allogeneic HSCT Autologous HSCT Graft versus host disease (GVHD)

back to top
Classical Hematology
Hemostasis and thrombosis
Acquired coagulopathy Inherited coagulopathy Inherited thrombophilia Venous thromboembolism (VTE)
Cytopenias
Aplastic anemia Autoimmune cytopenias Autoimmune thrombocytopenic purpura (ITP) Heparin-induced thrombocytopenia (HIT)
Hemolytic disorders
Atypical hemolytic-uremic syndrome (aHUS) Autoimmune hemolytic anemia (AIHA) Cold agglutinin disease Paroxysmal nocturnal hemoglobinuria (PNH)
Sickle cell anemia Thrombotic thrombocytopenic purpura (TTP)
Browse our complete index of pages

Additional Information

Created as a knowledge base for hematology & oncology providers, HemOnc.org is a collaborative wiki containing details about 100's of hematology/oncology drugs, and 1000's of treatment regimens. Content is added by hematology & oncology professionals, and undergoes continuous peer review.


Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.

Priorities of this project include:

Additional possibilities for this project may include:

  • Creating summaries of pivotal clinical trials
  • Prioritizing regimens by their efficacy and/or toxicity
  • Capturing historical regimens that were standard-of-care prior to 2005
  • Checklists for common clinical scenarios/diseases
  • Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory & imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects

The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.

Retrieved from "https://hemonc.org/w/index.php?title=Main_Page&oldid=22292"